



FORM PTO-1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/821,811

ATTY. DOCKET NO.: P0453.70115US01

FILING DATE: April 8, 2004

CONFIRMATION NO.: 9061

APPLICANT: Sanghvi et al.

GROUP ART UNIT: 1614

EXAMINER: Donna A. Jagoe

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		2007-0099946	A1	Doshan	05-03-2007
		2007-0265293	A1	Boyd et al.	11-15-2007

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Cancer Weekly Plus Newsletter (August 12, 1996)	
		<del>http://opioids.com/opiates.html</del>	
		<del>http://www.medscape.com/viewarticle/506798-5</del>	
		<del>http://www.medscape.com/viewarticle/442893-4</del>	
		YUAN et al., Methylalntrexone effects on morphine-induced inhibition in isolated guinea-pig and human intestine. Clin Pharm & Therapeut. 1995 Feb;57:138. Abstract PI-11.	
		ZIMMERMAN et al., Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3- hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem. 1994 Jul 22, 37(15):2262-5.	

EXAMINER:

/Donna Jagoe/

DATE CONSIDERED:

9/21/2008

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.J./ (09/21/2008)